Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation (ML20981)

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2009 by Tongji University.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborators:
Sun Yat-sen University
Shanghai Jiaotong University Affiliated Shanghai Chest Hospital
RenJi Hospital
Guangdong Provincial People's Hospital
Peking Union Medical College Hospital
Information provided by:
Tongji University
ClinicalTrials.gov Identifier:
NCT00874419
First received: April 1, 2009
Last updated: May 18, 2011
Last verified: August 2009
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: July 2011
  Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
No publications provided by Tongji University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):